Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
August 10, 2021 7:01 AM EDT
UBS analyst Esther Rajavelu downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Buy to Neutral with a price target of $109.00 (from $108.00).
The analyst comments "We are moving to Neutral from Buy following a strong 1H21 stock performance for BHVN, primarily driven by Nurtec... More
August 9, 2021 10:49 AM EDT
Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $140.00 (from $130.00) while maintaining an Outperform rating.
The analyst commented, "The Q2 performance validates our and our consultants initial views of the product and depth of need, and it... More
August 9, 2021 7:13 AM EDT
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.23), $0.49 worse than the analyst estimate of ($2.74). Revenue for the quarter came in at $92.93 million versus the consensus estimate of $78.13 million.
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
...
More
